Literature DB >> 27311100

Arylhydrazone derivatives of naproxen as new analgesic and anti-inflammatory agents: Design, synthesis and molecular docking studies.

Homa Azizian1, Zahra Mousavi2, Hamidreza Faraji2, Mohammad Tajik3, Kowsar Bagherzadeh4, Peyman Bayat5, Abbas Shafiee3, Ali Almasirad6.   

Abstract

A series of new arylidenehydrazone derivatives of naproxen were synthesized and evaluated for their analgesic and anti-inflammatory activities. Some of the synthesized analogues showed comparable activities when compared against naproxen for their analgesic and anti-inflammatory properties. 2-(6-methoxy-2-naphthyl)-N'-[(pyridine-4-yl)methylene]propanoic acid hydrazide 4j was found to be the most active analgesic agent. 2-(6-methoxy-2-naphthyl)-N'-[4-nitrobenzylidene]propanoic acid hydrazide 4g showed highest anti-inflammatory activity in comparison to the naproxen. Molecular modeling study of the synthesized compounds suggested that the designed molecules were well located and bound to the COX-1 and COX-2 active sites. Compound 4g showed the highest selectivity for COX-2 (RCOX-2/COX-1=1.94) and higher affinity rather than naproxen in COX-2 active site (RCOX-2/naproxen=1.28). Moreover, the structural analyses confirmed that the E-ap rotamer is the preferred structure for the arylidenehydrazone derivatives.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analgesic; Anti-inflammatory; AutodockVina; Cyclooxygenase; Hydrazone; Molecular modeling

Mesh:

Substances:

Year:  2016        PMID: 27311100     DOI: 10.1016/j.jmgm.2016.05.009

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  1 in total

1.  Synthesis of benzo[d]thiazole-hydrazone analogues: molecular docking and SAR studies of potential H+/K+ ATPase inhibitors and anti-inflammatory agents.

Authors:  Shi-Meng Wang; Gao-Feng Zha; K P Rakesh; N Darshini; T Shubhavathi; H K Vivek; N Mallesha; Hua-Li Qin
Journal:  Medchemcomm       Date:  2017-04-26       Impact factor: 3.597

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.